Alternate serotype adenovector provides long-term therapeutic gene expression in the eye

Molecular Vision

Volumn 14, Issue , 2008, Pages 2535-2546

  Hamilton, Melissa M ^a   Byrnes, Gordon A ^b   Gall, Jason G ^a   Brough, Douglas E ^a   King, C Richter ^a   Wei, Lisa L ^a  

^a GENVEC INC   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; LUCIFERASE; PIGMENT EPITHELIUM DERIVED FACTOR;

ADENOVIRUS; ADENOVIRUS 35; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENOME ANALYSIS; LONG TERM POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEROTYPE; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENETICS;

ADENOVIRIDAE; ANIMALS; CHOROIDAL NEOVASCULARIZATION; EYE; EYE PROTEINS; FEMALE; GENE THERAPY; GENETIC VECTORS; GENOME; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS; LUCIFERASES; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS; POLYMERASE CHAIN REACTION; SEROTYPING; SERPINS; TIME FACTORS; TRANSGENES;

EID: 58149464333     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109:1109-14.
2. Ambati J, Ambati B, Yoo S, Ianchulev S, Adamis A. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48:257-93.
3. Seddon JM. Epidemiology of age-related macular degeneration. Ryan JJ, editors. Retina. Vol. 2. St. Louis: Mosby; 2001. p. 1039-50.
4. Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341:667-78.
5. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005; 2:A17.
6. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Eye Diseases Prevalence Research Group., Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122:477-85.
7. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996; 80:9-14.
8. Vitale S, Cotch MF, Sperduto RD. Prevalence of visual impairment in the United States. JAMA 2006; 295:2158-63.
9. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005; 28:1649-55.
10. Eter N, Krohne TU, Holz FG. New pharmacologic approaches to therapy for age-related macular degeneration. BioDrugs 2006; 20:167-79.
11. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26:859-70.
12. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2006; 28:36-44.
13. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006; 19:361-72.
14. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-98.
15. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004; 24:699-705.
16. D'Amato RJ, Adamis AP. Angiogenesis inhibition in age-related macular degeneration. Ophthalmology 1995; 102:1261-2.
17. Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V, McVey D, Wei L, Campochiaro PA. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. Invest Ophthalmol Vis Sci 2002; 43:1610-5.
18. Mashhour B, Couton D, Perricaudet M, Briand P. In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther 1994; 1:122-6.
19. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35:2535-42.
20. Li T, Adamian M, Roof DJ, Berson EL, Dryja TP, Roessler BJ, Davidson BL. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci 1994; 35:2543-9.
21. Jomary C, Piper TA, Dickson G, Couture LA, Smith AE, Neal MJ, Jones SE. Adenovirus-mediated gene transfer to murine retinal cells in vitro and in vivo. FEBS Lett 1994; 347:117-22.
22. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular agerelated macular degeneration (AMD). Hum Gene Ther 2001; 12:2029-32.
23. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12:2029-32.
24. Hamilton MM, Brough DE, McVey D, Bruder JT, King CR, Wei LL. Repeated administration of adenovector in the eye results in efficient gene delivery. Invest Ophthalmol Vis Sci 2006; 47:299-305.
25. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17:167-76.
26. Chevez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23:7927-35.
27. Bennett J. Commentary: an aye for eye gene therapy. Hum Gene Ther 2006; 17:177-9.
28. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000; 6:3081-7.
29. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RV, Arafat W, Hughes JV, Siegal GP, Curiel DT. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2:524-30.
30. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6:879-85.
31. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9:553-66.
32. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20:1562-9.
33. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson DM. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum-and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004; 94:442-8.
34. Hasenburg A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001; 83:549-54.
35. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72:7909-15.
36. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J Infect Dis 1997; 175:697-700.
37. Law LK, Davidson BL. What does it take to bind CAR? Mol Ther 2005; 12:599-609.
38. Howitt J, Anderson CW, Freimuth P. Adenovirus interaction with its cellular receptor CAR. Curr Top Microbiol Immunol 2003; 272:331-64.
39. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94:3352-6.
40. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9:1408-12.
41. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77:9183-91.
42. Marttila M, Persson D, Gustafsson D, Liszewski MK, Atkinson JP, Wadell G, Arnberg N. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 2005; 79:14429-36.
43. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73:309-19.
44. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7.
45. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311:384-93.
46. Butman BT, Lizonova A, Brough DE, Sowers JM, Sheets R, Gall J, Newton P, Gomez P. Comprehensive characterization of the 293-ORF6 cell line. Dev Biol (Basel) 2006; 123:225-33.
47. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9:951-7.
48. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70:6497-501.
49. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188:253-63.
50. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007; 25:2074-84.
51. McVey D, Zuber M, Ettyreddy D, Yabe I, Bommersbach A, Grier R, Brough DE, King CR, Fultz M, Glenn A, Nabel GJ, Gall JG, Bumpers D, Bumpers B. Adenovirus 35 Vectors with Improved Transgene Capacity, and Ease of Production. in American Society of Gene Therapy. 2007. Seattle, WA.
52. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75:11284-91.
53. Raabe T, Olivier JP, Dickson B, Liu X, Gish GD, Pawson T, Hafen E. Biochemical and genetic analysis of the Drk SH2/SH3 adaptor protein of Drosophila. EMBO J 1995; 14:2509-18.
54. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6:1336-9.
55. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Melia M, Phipps S, Moffat D, Brazzell K, Liau G, Dixon KH, Campochiaro PA. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001; 159:313-20.
56. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Carrion M, Wei L, Campochiaro PA. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the bloodretinal barrier. Hum Gene Ther 2003; 14:129-41.
57. Carrion ME, Hamilton M, Harris B, Brough DE, Gehlbach P, King CR, Wei L. Ocular Sublocalization and Pharmacokinetics of Expression of Pigment Epithelium- Derived Factor in Murine Eyes Following Adenovirus-Based Intravitreous Gene Delivery. ARVO Annual Meeting; 2003 May 4-9; Fort Lauderdale (FL).
58. Carrion ME, Hamilton MM, Harris B, King CR, Mori K, Wei L. Ocular Pharmacokinetics of Pigment Epithelium-Derived Factor (PEDF) Following Adenovector-Based Gene Delivery Indicate That Low Doses of PEDF Are Therapeutic. ARVO Annual Meeting; 2005 May 1-5; Fort Lauderdale (FL).
59. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, Campochiaro PA. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998; 39:180-8.
60. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS, Cingolani C, Lai H, Wei L, Campochiaro PA. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther 2003; 10:637-46.
61. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KI, Raisler BJ, Hauswirth WW, Campochiaro PA. AAVmediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43:1994-2000.
62. Edelman JL, Castro MR. Quantitative image analysis of laserinduced choroidal neovascularization in rat. Exp Eye Res 2000; 71:523-33.
63. D'Amato RJ, Adamis AP. Angiogenesis inhibition in agerelated macular degeneration. Ophthalmology 1995; 102:1261-2.
64. Woolson RF, Clarke WR. Statistical methods for the analysis of biomedical data. 2nd. ed. New York: John Wiley & Sons, Inc; 2002. p. 277.
65. McVey D, Hamilton MM, Hsu C, King CR, Brough DE, Wei LL. Repeat Administration of Proteins to the Eye With a Single Intraocular Injection of an Adenovirus Vector. Mol Ther 2008; 16:1444-9.
66. Stellmach V, Crawford S, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98:2593-7.
67. Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002; 99:8909-14.
68. Mallam JN, Hurwitz MY, Mahoney T, Chevez-Barrios P, Hurwitz RL. Efficient gene transfer into retinal cells using adenoviral vectors: dependence on receptor expression. Invest Ophthalmol Vis Sci 2004; 45:1680-7.
69. Rasmussen HS, Rasmussen CS, Macko J. VEGF gene therapy for coronary artery disease and peripheral vascular disease. Cardiovasc Radiat Med 2002; 3:114-7.
70. Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G. Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr Opin Mol Ther 2002; 4:476-81.
71. McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, Kuhn JA. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 2005; 12:825-30.
72. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22:592-601.
73. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler P, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RRA. Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004; 10:5747-53.
74. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular agerelated macular degeneration (AMD). Hum Gene Ther 2001; 12:2029-32.
75. Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C, Perkins J, Kay MA. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995; 2:151-5.
76. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J Virol 1995; 69:2004-15.
77. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3:137-44.
78. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91:4407-11.
79. Miwa T, Nonaka M, Okada N, Wakana S, Shiroishi T, Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 1998; 48:363-71.
80. Tsujimura A, Shida K, Kitamura M, Nomura M, Takeda J, Tanaka H, Matsumoto M, Matsumiya K, Okuyama A, Nishimune Y, Okabe Y, Seya T. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J 1998; 330:163-8.
81. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci 2000; 41:4195-202.
82. McLaughlin BJ, Fan W, Zheng JJ, Cai H, Del Priore LV, Bora NS, Kaplan HJ. Novel role for a complement regulatory protein (CD46) in retinal pigment epithelial adhesion. Invest Ophthalmol Vis Sci 2003; 44:3669-74.
83. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34:3579-84.
84. Mori K, Okuda A, Ito T, Takita H, Imai D, Yoneya S, Gehlbach PL, Wei LL. Empty E1-, E3-, E4+ and Empty E1-, E3-, E4- Adenoviral Vectors Inhibit Retinal Neovascularization. ARVO Annual Meeting; 2005 May 1-5; Fort Lauderdale (FL).